Jun 11, 2020 / 01:00PM GMT
Operator
This meeting is being recorded, Dupixent R&D Investor event. (Operator Instructions) I would now like to turn it over to Felix Lauscher from Sanofi Investor Relations.
Felix Lauscher - Sanofi - Head of IR North America & Asia
Thank you, Natalie. Good morning, and afternoon to everyone, and welcome to our R&D webinar. Thank you for joining us on the third of our 5-part series of interactive webcast events to highlight Sanofi's progress in R&D. Let me remind you Sanofi's virtual R&D event is scheduled for Tuesday, June 23.
Now returning to today's event dedicated to Dupixent, our priority asset. If you are unable to view the presentation during the webinar, you can find the slides to this event on the Investors page of our website, sanofi.com.
Moving to the second slide, Slide 2. I would like to remind you that information presented during this event contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. I refer you to our
Sanofi SA Dupixent R&D Investor Event Transcript
Jun 11, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers